Assembly Biosciences Inc., a company testing the limits of sustained virologic response in people with chronic hepatitis B virus infection after they discontinue treatment, said nearly all participants in an ongoing phase II study returned to having detectable viral loads after going off a regimen featuring the company's core inhibitor, vebicorvir.
DUBLIN – Canakinumab, an interleukin-1 beta (IL-1beta) inhibitor, has joined a growing list of immunomodulatory therapies that have failed to demonstrate efficacy in COVID-19. Novartis AG said that an interim analysis showed the drug did not meet the primary endpoint of clinical response.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Anavex, Assembly, Boehringer Ingelheim, Equillium, Homology, Humanigen, Janssen, Novartis, Pfizer, Puma, Seres, Viela.
New updates from a dynamic late-phase systemic lupus erythematosus pipeline shared at this week's American College of Rheumatology annual meeting and beyond showed a robust field of potential new treatments nearing the finish line.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Alzinova, Biomx, Calithera, Cassava, Ionis, Nanology, Nektar, Pfizer, Soleno, Vtv.
HONG KONG – Aprinoia Therapeutics Inc. is poised to start phase III clinical trials for its positron emission tomography (PET) imaging tracer 18F-APN-1607 in China, after receiving the green light from the National Medical Products Administration.
Nanobiotix SA ’s achieved promising early results in several clinical trials for its first-in-class radioenhancer. Despite the pandemic, trials in head and neck squamous cell cancer, hepatocellular carcinoma, pancreatic cancer, and rectal cancer remain on track, the Cambridge, Mass., and Paris-based company reported at ASTRO 2020.
Aurinia Pharmaceuticals Inc. is suspending further development of voclosporin ophthalmic solution (VOS) for dry eye syndrome after a dose-ranging trial of the candidate failed to meet its primary endpoint of improving a measure of the condition after four weeks of treatment.
RSS
